BrightGene Bio-Medical Technology Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Borui Biomedical (Suzhou) Co., Ltd. (abbreviated as Borui Pharmaceutical; stock code: 688166) is an innovative pharmaceutical enterprise that participates in international competition. The company relies on research and development driven, focusing on first-time, difficult to replicate, characteristic raw materials, complex formulations, and innovative new drugs, continuously creating high-tech barriers, and gradually establishing a business system that integrates raw materials and formulations, combines generic and innovative drugs, and places equal emphasis on the international and domestic markets. It is committed to meeting the unmet clinical needs of patients worldwide. Borui Pharmaceuticals aims to "continuously innovate and protect health", providing patients with valuable products. Through years of accumulation, drug technology research and development platforms have been formed, including fermentation semi synthesis platforms, multi chiral drug platforms, non biological macromolecule platforms, pharmaceutical device combination platforms, and coupled drug platforms. The products cover fields such as antifungal, antiviral, immunosuppressive, anti-tumor, cardiovascular and cerebrovascular, respiratory, iron supplements, veterinary drugs, and excipients. The company's drug production system has passed the official GMP certification of China, the United States, the European Union, Japan and South Korea, and its products cover China, the European Union, the United States, Japan and South Korea, as well as other "the Belt and Road" countries or regions. The company has independently developed and produced multiple pharmaceutical intermediates and API products, which have been DMF registered and cited by customers in major international standardized market countries such as the United States, Europe, Japan, and South Korea, and China, establishing a product line with global competitive advantages. Borui Pharmaceuticals, with its strong research and development capabilities as the cornerstone, has achieved rapid development through its internationally aligned cGMP production quality system, as well as its global registration and commercialization capabilities. At the same time, it has connected the entire industry chain from "starting materials → difficult intermediates → characteristic raw materials → preparation", becoming a leading enterprise and international pioneer in the Chinese pharmaceutical industry. Borui Pharmaceutical adheres to the principle of "people-oriented" and provides broad development space for various talents. It provides patients with high-quality, effective, safe and reliable cost-effective drugs, and creates a warm and healthy social living environment. Based in China and looking internationally, Borui Pharmaceuticals is committed to building a more internationally competitive high-tech pharmaceutical enterprise that integrates research and development, production, technical services, and sales. |
| Headquarter | Suzhou |
| Establish Date | 10/26/2001 |
| Listed Code | 688166.SH |
| Listed Date | 11/8/2019 |
| Chairman | Yuan Jiandong. |
| CEO | Yuan Jiandong. |
| Website | www.bright-gene.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
